Talphera (TLPH)
Develops hospital and dialysis therapies, led by Niyad for renal-replacement anticoagulation.
Something off on this page? Send us feedback.
Develops hospital and dialysis-care drug candidates, led by Niyad for regional anticoagulation during renal replacement therapy. The U.S.-focused development organization has no approved product generating material sales and relies on partners for manufacturing and selected product rights.
Develops a portfolio of hospital and dialysis-care candidates for medically supervised settings, led by Niyad, an investigational nafamostat formulation for regional anticoagulation during continuous renal replacement therapy. Niyad is in a U.S. registrational study for adults who cannot tolerate heparin or face a bleeding risk.
Also advances LTX-608, a separate nafamostat formulation in preclinical development, and holds U.S. rights to Fedsyra and PFS-02, ready-to-use ephedrine and phenylephrine syringes for anesthesia-related hypotension. The syringe products are licensed from France-based Laboratoire Aguettant.
Operates as a development organization, concentrating its limited staff and spending on clinical development, regulatory work and outsourced production rather than a diversified commercial business. Niyad is its only registrational-stage program, and the nafamostat candidates depend on a single source for API and finished product, with the finished-goods CDMO in China.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.1M · Total debt $0 · Total assets $26.8M · Shareholders' equity $14.4M
- Revenue
- $0
- Operating income
- −$3.9M
- Net income
- −$4.3M
No dividends on record.
| Institutions51 holders · as of Mar 31, 2026 | 42.13% | 21.87M shares | |
| Insiders11 holders · as of Jun 24, 2026 | 2.17% | 1.13M shares | |
| Strategic holders1 holder · as of Sep 12, 2025 | 17.51% | 9.09M shares | |
| Otherremainder | 38.19% | 19.82M shares |
51.91M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
CorMedix Inc.Strategic10 percent owner | 17.51% | 9.09M | 13Dfiled Sep 12, 2025 ↗ |
Aigh Capital Management LLCInstitution | 8.98% | 4.66M | 13Fas of Mar 31, 2026 |
Rock Springs Capital Management LPInstitution | 6.91% | 3.59M | 13Fas of Mar 31, 2026 |
Nantahala Capital Management, LLCInstitution | 6.73% | 3.49M | 13Fas of Mar 31, 2026 |
Rosalind Advisors, Inc.Institution | 6.46% | 3.35M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 13, 2026 | Vincent J. Angotti | director, officer: CHIEF EXECUTIVE OFFICER | +213,310 | $0.5860 |
| Feb 12, 2026 | Raffi Asadorian | officer: Chief Financial Officer | +45,000 | $0.8123 |
| Feb 12, 2026 | Badri N. Dasu | officer: Chief Engineering Officer | +35,000 | $0.8123 |
| Feb 12, 2026 | Shakil Aslam | officer: Chief Medical Officer | +35,000 | $0.8123 |
| Feb 12, 2026 | Vincent J. Angotti | director, officer: CHIEF EXECUTIVE OFFICER | +105,364 | $0.8123 |
- Fresenius Medical Care (ADR)
Core CRRT regional-anticoagulation alternative using citrate.
- Amneal Pharmaceuticals
U.S. hospital injectables span both planned vasopressor actives.
- Pfizer
Heparin injection supplies the established CRRT anticoagulation option.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Talphera | $1.20 | +1.69% | $62.3M | — | — | 62,279.5 | — |
| Fresenius Medical Care (ADR) | $22.55 | −0.49% | $12.17B | 11.7 | 16.4 | 0.5 | −0.7% |
| Amneal Pharmaceuticals | $18.01 | −0.33% | $5.77B | 37.0 | 18.1 | 1.8 | +9.9% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 37.0 | 16.4 | 1.8 | +2.6% |